Miura, Shoko
Tsuchie, Keiko
Fukushima, Michiyo
Arauchi, Ryosuke
Tsumori, Toshiko
Otsuki, Koji
Hayashida, Maiko
Hashioka, Sadayuki
Wake, Rei
Miyaoka, Tsuyoshi
Inagaki, Masatoshi
Oh-Nishi, Arata
Article History
Received: 5 November 2020
Revised: 28 January 2021
Accepted: 8 February 2021
First Online: 31 March 2021
Competing interests
: Shimane University has submitted a patent application (PCT/JP2020/017552) for the use of the compound described in this paper. M.I. has received grants from Research for Promotion of Cancer Control Programs during the conduct of the study. He has received lecture fees from Technomics, Fuji Keizai, Novartis, Yoshitomiyakuhin, Pfizer, MSD, Meiji Seika Pharma, Eisai, Otsuka, Sumitomo Dainippon Pharma, Mochida, Janssen, Takeda, and Eli Lilly. The institution of M.I. received grants or research support from Otsuka, Eisai, Daiichi-Sankyo, Pfizer, Astellas, MSD, Takeda, Fujifilm, Shionogi, and Mochida. A.O.-N. is listed as an inventor of this patent. A.O.-N. is CEO & CTO of RESVO Inc. and has >5% of RESVO Inc. shares but had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to <i>Pediatric Research</i> publication policy. Other authors have no competing interests to declare.
: Patient consent was not required.